Oppenheimer Starts Clearside Biomedical (CLSD) at Outperform

Oppenheimer analyst Andreas Argyrides initiates coverage on Clearside Biomedical (NASDAQ: CLSD) with a Outperform rating and a price target of $5.00.

For an analyst ratings summary and ratings history on Clearside Biomedical click here. For more ratings news on Clearside Biomedical click here.

Shares of Clearside Biomedical closed at $1.08 yesterday.

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
• Canaccord Starts Galiano Gold (GAU:CN) at Buy